Oasis Diagnostics Corporation

15720 NE 31st Avenue, 98686 Vancouver, WA

Telephone +1 360 5461563
Fax +1 360 5461581

This company is co-exhibitor of
Messe Düsseldorf North America


Hall map

MEDICA 2016 hall map (Hall 3): stand D15-5

Fairground map

MEDICA 2016 fairground map: Hall 3

Our range of products

Product categories

  • 03  Diagnostics
  • 03.02  Immunochemistry (Immunology)
  • 03.02.11  Drugs of abuse / Toxicology

Drugs of abuse / Toxicology

Our products

Product category: Drugs of abuse / Toxicology

Versi•SAL® Saliva Collection Device

Versi•SAL® devices are for controlled and standardized fluid collection that incorporates a proprietary interchangeable absorbent pad for immediate saliva (and other fluid) collections.

Versi•SAL™ is available in a number of configurations. The “standard” Versi•SAL™ device includes a plastic compression tube which delivers saliva specimen directly into a standard Eppendorf 2 mL centrifuge tube. A second variation includes a split sample Bifurcating Compression Tube for expressing into 2 sample tubes simultaneously.

The Versi•SAL®-L Travel Cover configuration maintains sample integrity for long shipments, thereby relieving the need to remove the sample from the absorbent collection pad at collection point. Further customization can come in thickness of the pad allowing control over maximum sample volume (1.2 mL to 1.4 mL).

Instructions for Use

Versi•SAL® works by placing the device pad under the tongue and collecting saliva (oral fluid) until a novel sample sufficiency indicator (b, above) is triggered [2-3 minutes]. The collector is then pushed down firmly into the compression tube (c) supplied until the Versi•SAL® pad is totally compressed. This action forces the saliva specimen through an outlet (d) into a graduated Eppendorf-style tube (e). The sample obtained may then be tested immediately in point-of-care applications or sent to a laboratory for subsequent testing.

1.Take the collection device (a) and place the absorbent pad UNDER the tongue and collect saliva until the sample sufficiency indicator (b) is triggered. At this point the visual line disappears indicating that an adequate volume of saliva has been collected for subsequent analysis, testing or storage for later analysis.
2.Left frame above shows the sample sufficiency indicator BEFORE sufficient fluid (saliva) has been collected. Right frame above shows the sample sufficiency indicator AFTER an adequate volume of saliva specimen has been collected.
3.Push the Versi•SAL® device (a) down into the compression tube (c) and push until the device can be pushed no further down (the pad will appear totally compressed and saliva will begin to flow into the collection tube.)
4.This shows the Versi•SAL® device with fully compressed absorbent pad material. Saliva will be flowing from the sample pad, through the compression tube (d) and into the Eppendorf-style tube (e).
5.Remove the Eppendorf-style tube (e) from the outlet of the compression tube (d) and close cap.
6.Use the saliva sample collected for immediate (point-of-care testing) applications, send to a qualified laboratory for additional testing or store in a freezer at -20° or -70° Celsius for later analysis.

More Less

About us

Company details

Oasis Diagnostics® Corporation was founded in 2002 to address a growing need for non-invasive saliva based technology for rapid testing, sample collection, and molecular diagnostics [DNA, RNA and proteins]. The Company is dedicated to meeting the need for more effective screening tools, which may be applied to the early detection of diseases and medical disorders, utilizing non-invasive test specimens, particularly oral fluids (saliva).

Oral Fluid Products

A major focus area for the company is our commitment to providing timely and superior quality diagnostic and screening solutions. Oasis Diagnostics® Corporation has developed a unique proprietary range of oral fluid products which includes the *VerOFy® oral fluid rapid test platform, the *Versi•SAL® split sample saliva / oral fluid collection device, the DNA•SAL™ Salivary DNA collection device, and Super•SAL™, a novel device for RNA and or protein collection for genomic applications or proteomics and the Sali•Chek™ hand held electronic reading device for lateral flow test reading. Additional devices are under development.

The Company is also the exclusive North American distributor for a novel genomic product line from ViennaLab Diagnostics (Vienna, Austria), which is based upon pharmacogenomics and genetic predisposition. Products include rapid strip based assays for KRAS mutations, BRAF, Fc Gamma Receptors, Congenital Adrenal Hyperplasia [CAH], hemochromatosis, Alzheimer's disease, cardiovascular disease (CVD), Familial Mediterranean Fever (FMF), Gaucher's disease, sugar (glucose / fructose) intolerance, CYP2D6, HLA-B27, cystic fibrosis and others.

Pharmacogenomic Tests

Newer pharmacogenomic tests include novel immunoassays for identification of genotypes associated with response to Coumadin anti-coagulants including Warfarin, treatment response to HIV HAART and 5-fluorouracil chemotherapy treatment response. Recently the Company announced a partnership to distribute products from Operon S.A. ( Zaragoza, Spain). Products in this range include strip format genomic tests for celiac disease and AZF micro-deletions in chromosome Y for male fertility.

Oasis Diagnostics® Corporation was founded on the philosophy that "early detection is the key to disease prevention efforts," so we are constantly searching for innovative new products and potential partners from many parts of the world, which fit into this strategic directive with the single purpose of improving the quality of healthcare for our global customers.

With this particular emphasis in mind, Oasis Diagnostics® Corporation is always open to discussing new business opportunities with potential collaborative partners, which fit into our Corporate strategy. Sali•Chek™, VerOFy®, DNA•SAL™, Versi•SAL®, 4saliva®, Super•SAL™ and Oasis Diagnostics® are trademarks of Oasis Diagnostics® Corporation. These devices are the subject of a series of US and international patent submissions and issued patents.

More Less